CNSPライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:40):

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors...

Stats
本日の出来高	30 398.00
平均出来高	394 187
時価総額	2.29M
EPS	$0 ( 2024-04-01 )
次の収益日	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0200
ATR14	$0.00400 (1.86%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-08	Mahery Amy	Buy	17 500	Restricted Stock Units
2024-04-08	Mahery Amy	Buy	17 500	Option to purchase common stock
2024-04-08	Keyes Jeffry R.	Buy	17 500	Restricted Stock Units
2024-04-08	Keyes Jeffry R.	Buy	17 500	Option to purchase common stock
2024-04-08	Gumulka Jerzy	Buy	17 500	Restricted Stock Units

INSIDER POWER
95.23
Last 96 transactions
Buy: 4 147 286 \| Sell: 1 591 936

ボリューム相関

長: 0.11 (neutral)

短: -0.57 (weak negative)

Signal:(53.182) Neutral

CNS Pharmaceuticals Inc 相関

10 最も正の相関
TDAC	0.958
GAINL	0.947
THMO	0.941
HUSN	0.939
UK	0.935
RMRM	0.924
BIOL	0.924
KBSF	0.922
GRNV	0.921
APOP	0.918

10 最も負の相関
BOCH	-0.96
SHSP	-0.937
HEES	-0.92
LMST	-0.914
LOPE	-0.914
KBWP	-0.908
PI	-0.908
LMRK	-0.905
HOLX	-0.905
INNV	-0.901

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

CNS Pharmaceuticals Inc 相関 - 通貨/商品

0.39
( neutral )

0.59
( weak )

0.00
( neutral )

0.08
( neutral )

CNS Pharmaceuticals Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$-4 134.00 (0.00 %)
EPS:	$-5.00

FY	2023
収益:	$0
総利益:	$-4 134.00 (0.00 %)
EPS:	$-5.00

FY	2022
収益:	$0
総利益:	$-11 756.00 (0.00 %)
EPS:	$-11.22

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-15.34

Financial Reports:

No articles found.

CNS Pharmaceuticals Inc

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.